Gordon J. Freeman, PhD, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology

Gordon J. Freeman, PhD

On February 21, 2024, it was announced that the American Association for Cancer Research (AACR) will award Gordon J. Freeman, PhD, with the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology during the AACR Annual Meeting 2024 to be held April 5-10 at the San Diego Convention Center in San Diego, California. Freeman is a Professor of Medicine in the Department of Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts. He is being recognized for his ground-breaking contributions to the discovery of the T-cell programmed death-1 receptor (PD-1) signaling pathway and the PD-1 ligands, PD-L1 and PD-L2; for spotlighting the involvement of this pathway in tumor evasion of immunosurveillance; and for demonstrating that blocking this pathway can provoke an antitumor immune response. His extraordinary work has led to the development of immunotherapies for cancer, autoimmune diseases, and transplant rejection.

Login Or Register To Read Full Story